Taurochenodeoxycholic acid alleviates obesity-induced endothelial dysfunction
Authors' conclusion
This study suggests CDCA as a promising biomarker for identification of obesity-induced ED. Taurochenodeoxycholic acid demonstrates significant therapeutic potential for alleviating various forms of obesity-induced ED.
Study context
- Population
- Non-hypertensive obese patients; ex vivo arterioles from omental adipose tissue
- Participants
- 213 patients
- Comparison
- Metabolically healthy obesity (MHO) vs metabolically unhealthy obesity (MUO)
- Outcome
- Obesity-induced ED
Main finding
As reported in the abstract
- Obesity-induced endothelial dysfunction (ED) in non-hypertensive obese (NHO) patients lacked correlations with many traditional CV risk factors
- MHO and MUO exhibited similar ED and metabolomic profile characteristics
- Serum bile acids, particularly CDCA, negatively correlated with ED
- Taurochenodeoxycholic acid (TCDCA) protected against obesity-induced ED and hypertension
- Endothelial Farnesoid X receptor (FXR) deletion aggravated obesity-induced ED and hypertension, negating benefits of bariatric surgery or TCDCA
- TCDCA-FXR activation upregulated ATF4 transcription (suppressed by PHB1), enhancing serine and one-carbon metabolism
Original publication
Taurochenodeoxycholic acid alleviates obesity-induced endothelial dysfunction. Eur Heart J. Published 3 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →